Besides, the board has also declared a final dividend of Rs 23 (460 per cent) per equity share of Rs 5 each including the special dividend of Rs 15 per equity share.
At 9:30 AM, the shares were ruling 8 per cent higher at Rs 2,852 apiece as against a 0.4 per cent gain in the benchmark S&P BSE Sensex.
Meanwhile, Torrent Pharma posted a net loss of Rs 118 crore for the fourth quarter ended March 31, 2022 (Q4FY22) on the back of headwinds in its EU business and discontinuation of liquids business in the US. The company had registered a profit after tax (PAT) of Rs 324 crore in the corresponding quarter of last year.
The company's revenue, however, grew by 10 per cent to Rs 2,131 crore in Q4FY22 aided by strong growth momentum in branded generic markets. Torrent Pharma's revenue for Q4FY21 was Rs 1,937 crore.
The branded businesses contributed to 70 per cent of total revenues in Q4 and grew by 15 per cent with India and Brazil continuing on a strong footing. The US business registered sequential growth aided mainly by launch of a new product, the company said. "While our EU business faced some headwinds, we remain optimistic that the cost efficiency measures being taken will bring us back to growth in this market in the coming quarters," the management said.
As on March 31, 2022, Torrent Pharma had 57 abbreviated new drug applications (ANDAs) pending approval with US FDA and five tentative approvals received in Q4. During the quarter, six ANDAs were filed while one was approved.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app